Disciplina de Endocrinologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Departamento de Diagnóstico por Imagem, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Diabetes Res Clin Pract. 2021 Jun;176:108867. doi: 10.1016/j.diabres.2021.108867. Epub 2021 May 21.
Maturity-Onset Diabetes of the Young (MODY) caused by glucokinase (GCK) mutations is characterized by lifelong mild non-progressive hyperglycemia, with low frequency of coronary artery disease (CAD) compared to other types of diabetes. The aim of this study is to estimate cardiovascular risk by coronary artery calcification (CAC) score in this group.
Twenty-nine GCK-MODY cases, 26 normoglycemic controls (recruited among non-affected relatives/spouses of GCK mutation carriers), and 24 unrelated individuals with type 2 diabetes were studied. Patients underwent CAC score evaluation by computed tomography and were classified by Agatston score ≥ or < 10. Framingham Risk scores of CAD in 10 years were calculated.
Median [interquartile range] CAC score in GCK-MODY was 0 [0,0], similar to controls (0 [0,0], P = 0.49), but lower than type 2 diabetes (39 [0, 126], P = 2.6 × 10). A CAC score ≥ 10 was seen in 6.9% of the GCK group, 7.7% of Controls (P = 1.0), and 54.2% of individuals with type 2 diabetes (P = 0.0006). Median Framingham risk score was lower in GCK than type 2 diabetes (3% vs. 13%, P = 4 × 10), but similar to controls (3% vs. 4%, P = 0.66).
CAC score in GCK-MODY is similar to control individuals from the same family and/or household and is significantly lower than type 2 diabetes. Besides demonstrating low risk of CAD in GCK-MODY, these findings may contribute to understanding the specific effect of hyperglycemia in CAD.
由葡萄糖激酶(GCK)突变引起的青少年发病的成年型糖尿病(MODY)的特点是终生轻度非进行性高血糖,与其他类型的糖尿病相比,冠心病(CAD)的发生率较低。本研究旨在通过冠状动脉钙化(CAC)评分评估该组患者的心血管风险。
研究了 29 例 GCK-MODY 病例、26 例血糖正常对照者(从 GCK 基因突变携带者的无相关亲属/配偶中招募)和 24 例 2 型糖尿病无关个体。患者接受计算机断层扫描 CAC 评分评估,并根据 Agatston 评分进行分类,得分≥10 或<10。计算了 10 年内 CAD 的Framingham 风险评分。
GCK-MODY 的中位[四分位间距]CAC 评分(0 [0,0])与对照组相似(0 [0,0],P=0.49),但低于 2 型糖尿病(39 [0,126],P=2.6×10)。GCK 组有 6.9%的患者 CAC 评分≥10,对照组为 7.7%(P=1.0),2 型糖尿病患者为 54.2%(P=0.0006)。GCK 的Framingham 风险评分中位数低于 2 型糖尿病(3%比 13%,P=4×10),但与对照组相似(3%比 4%,P=0.66)。
GCK-MODY 的 CAC 评分与来自同一家庭的对照组个体相似,明显低于 2 型糖尿病。除了表明 GCK-MODY 患者 CAD 的风险较低外,这些发现还可能有助于了解高血糖对 CAD 的具体影响。